Vanda Pharmaceuticals
Clinical trials sponsored by Vanda Pharmaceuticals, explained in plain language.
-
Promising ichthyosis drug trial halted early
Disease control TerminatedThis study tested a drug called imsidolimab (ANB019) for people with ichthyosis, a skin condition causing severe dryness and scaling. The trial was stopped early after enrolling only 5 participants. The goal was to see if the drug could reduce skin redness and scaling compared to…
Phase: PHASE2 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 06:54 UTC
-
Psoriasis drug trial halted midway: what happened?
Disease control TerminatedThis study tested the long-term safety and effectiveness of imsidolimab, an experimental drug, in adults with generalized pustular psoriasis (GPP), a severe skin condition causing painful pustules. Participants had already completed an earlier phase of the study. The trial was te…
Phase: PHASE3 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
Cancer rash drug trial halted after just 4 patients
Symptom relief TerminatedThis study tested a drug called imsidolimab (ANB019) to treat acne-like skin rashes that can happen as a side effect of certain cancer treatments. The trial planned to include people with cancer who were getting EGFR or MEK inhibitor therapy and had at least 20 facial bumps. Howe…
Phase: PHASE2 • Sponsor: Vanda Pharmaceuticals • Aim: Symptom relief
Last updated May 26, 2026 06:52 UTC